SIRs for tAML, overall and by calendar time, by initial chemotherapy with or without radiotherapy for selected first primary malignancies in adulthood, 9 SEER registries, 1975-2008
| . | . | . | . | By calendar period . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| . | Total . | 1975-1982 . | 1983-1990 . | 1991-1998 . | 1999-2008 . | ||||||
| First primary malignancy . | N . | SIR* . | ERR ratio (95% CI)† . | N . | SIR* . | N . | SIR* . | N . | SIR* . | N . | SIR* . |
| Lung, bronchus | |||||||||||
| Chemotherapy without radiotherapy | 14 | 4.24‡ | 1.00 (referent) | <3 | 3.13 | 3 | 4.48 | 6 | 6.16‡ | 4 | 3.00 |
| Chemotherapy with radiotherapy | 51 | 8.17‡ | 1.99 (0.97-4.96) | 6 | 15.06‡ | 9 | 8.93‡ | 17 | 6.91‡ | 19 | 8.01‡ |
| Female breast | |||||||||||
| Chemotherapy without radiotherapy | 96 | 3.70‡ | 1.00 (referent) | 20 | 3.42‡ | 23 | 2.80‡ | 32 | 4.18‡ | 21 | 4.98‡ |
| Chemotherapy with radiotherapy | 127 | 5.64‡ | 1.38 (0.98-1.98) | 8 | 4.33‡ | 16 | 4.22‡ | 50 | 5.55‡ | 53 | 6.73‡ |
| Ovary | |||||||||||
| Chemotherapy without radiotherapy | 63 | 8.00‡ | 1.00 (referent) | 24 | 15.54‡ | 17 | 6.87‡ | 11 | 4.59‡ | 11 | 7.52‡ |
| Chemotherapy with radiotherapy | 9 | 21.80‡ | 2.02 (0.89-4.10) | 7 | 28.30‡ | <3 | 11.78 | 0 | § | <3 | 32.22 |
| Hodgkin lymphoma | |||||||||||
| Chemotherapy without radiotherapy | 38 | 16.08‡ | 1.00 (referent) | 9 | 15.68‡ | 18 | 24.87‡ | 4 | 5.57‡ | 7 | 20.14‡ |
| Chemotherapy with radiotherapy | 20 | 17.85‡ | 0.89 (0.47-1.60) | 5 | 18.42‡ | 4 | 14.26‡ | 7 | 21.41‡ | 4 | 16.57‡ |
| Non-Hodgkin lymphoma | |||||||||||
| Chemotherapy without radiotherapy | 130 | 6.32‡ | 1.00 (referent) | 14 | 3.74‡ | 31 | 5.17‡ | 52 | 7.90‡ | 33 | 7.80‡ |
| Chemotherapy with radiotherapy | 28 | 4.33‡ | 0.61 (0.36-0.96) | 0 | § | 6 | 3.69‡ | 7 | 3.01‡ | 15 | 10.43‡ |
| Myeloma | |||||||||||
| Chemotherapy without radiotherapy | 46 | 10.26‡ | 1.00 (referent) | 15 | 16.19‡ | 14 | 12.32‡ | 7 | 5.01‡ | 10 | 9.77‡ |
| Chemotherapy with radiotherapy | 16 | 10.95‡ | 1.02 (0.52-1.85) | 5 | 17.90‡ | 5 | 13.33‡ | 3 | 6.41‡ | 3 | 8.85‡ |
| . | . | . | . | By calendar period . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| . | Total . | 1975-1982 . | 1983-1990 . | 1991-1998 . | 1999-2008 . | ||||||
| First primary malignancy . | N . | SIR* . | ERR ratio (95% CI)† . | N . | SIR* . | N . | SIR* . | N . | SIR* . | N . | SIR* . |
| Lung, bronchus | |||||||||||
| Chemotherapy without radiotherapy | 14 | 4.24‡ | 1.00 (referent) | <3 | 3.13 | 3 | 4.48 | 6 | 6.16‡ | 4 | 3.00 |
| Chemotherapy with radiotherapy | 51 | 8.17‡ | 1.99 (0.97-4.96) | 6 | 15.06‡ | 9 | 8.93‡ | 17 | 6.91‡ | 19 | 8.01‡ |
| Female breast | |||||||||||
| Chemotherapy without radiotherapy | 96 | 3.70‡ | 1.00 (referent) | 20 | 3.42‡ | 23 | 2.80‡ | 32 | 4.18‡ | 21 | 4.98‡ |
| Chemotherapy with radiotherapy | 127 | 5.64‡ | 1.38 (0.98-1.98) | 8 | 4.33‡ | 16 | 4.22‡ | 50 | 5.55‡ | 53 | 6.73‡ |
| Ovary | |||||||||||
| Chemotherapy without radiotherapy | 63 | 8.00‡ | 1.00 (referent) | 24 | 15.54‡ | 17 | 6.87‡ | 11 | 4.59‡ | 11 | 7.52‡ |
| Chemotherapy with radiotherapy | 9 | 21.80‡ | 2.02 (0.89-4.10) | 7 | 28.30‡ | <3 | 11.78 | 0 | § | <3 | 32.22 |
| Hodgkin lymphoma | |||||||||||
| Chemotherapy without radiotherapy | 38 | 16.08‡ | 1.00 (referent) | 9 | 15.68‡ | 18 | 24.87‡ | 4 | 5.57‡ | 7 | 20.14‡ |
| Chemotherapy with radiotherapy | 20 | 17.85‡ | 0.89 (0.47-1.60) | 5 | 18.42‡ | 4 | 14.26‡ | 7 | 21.41‡ | 4 | 16.57‡ |
| Non-Hodgkin lymphoma | |||||||||||
| Chemotherapy without radiotherapy | 130 | 6.32‡ | 1.00 (referent) | 14 | 3.74‡ | 31 | 5.17‡ | 52 | 7.90‡ | 33 | 7.80‡ |
| Chemotherapy with radiotherapy | 28 | 4.33‡ | 0.61 (0.36-0.96) | 0 | § | 6 | 3.69‡ | 7 | 3.01‡ | 15 | 10.43‡ |
| Myeloma | |||||||||||
| Chemotherapy without radiotherapy | 46 | 10.26‡ | 1.00 (referent) | 15 | 16.19‡ | 14 | 12.32‡ | 7 | 5.01‡ | 10 | 9.77‡ |
| Chemotherapy with radiotherapy | 16 | 10.95‡ | 1.02 (0.52-1.85) | 5 | 17.90‡ | 5 | 13.33‡ | 3 | 6.41‡ | 3 | 8.85‡ |
Exact cell counts with <3 patients are suppressed to protect patient confidentiality. Includes first primary malignancies after which at least 50 tAMLs were reported.
SIRs are unadjusted.
Derived from Poisson regression models adjusted for age at first diagnosis of primary malignancy, receipt of initial radiotherapy, sex (for lung and bronchus, Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloma), stage (for lung and bronchus, female breast, ovary), and latency (overall: 1.0-4.9, 5.0-9.9, 10+ years, except for lung and bronchus: 1-4.9, 5+ years).
Indicates P < .05.
Indicates SIR not presented because of zero observed cases.